184 related articles for article (PubMed ID: 23326194)
21. Ligand-Installed Nanocarriers toward Precision Therapy.
Mi P; Cabral H; Kataoka K
Adv Mater; 2020 Apr; 32(13):e1902604. PubMed ID: 31353770
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle-mediated tumor vaccines for personalized therapy: preparing tumor antigens
Li Q; Li J; Song S; Chen W; Shen X; Li S; Xing D
J Mater Chem B; 2021 Mar; 9(10):2352-2366. PubMed ID: 33659970
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics advancing personalized nanomedicine in cancer therapy.
Liu S
Adv Drug Deliv Rev; 2012 Oct; 64(13):1532-43. PubMed ID: 22921595
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in "smart" delivery systems for extended drug release in cancer therapy.
Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR
Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657
[TBL] [Abstract][Full Text] [Related]
25. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.
Gonzalez-Valdivieso J; Girotti A; Schneider J; Arias FJ
Int J Pharm; 2021 Apr; 599():120438. PubMed ID: 33662472
[TBL] [Abstract][Full Text] [Related]
26. Critical clinical gaps in cancer precision nanomedicine development.
Gan WW; Chan LW; Li W; Wong TW
J Control Release; 2022 May; 345():811-818. PubMed ID: 35378214
[TBL] [Abstract][Full Text] [Related]
27. Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy.
Jo SD; Ku SH; Won YY; Kim SH; Kwon IC
Theranostics; 2016; 6(9):1362-77. PubMed ID: 27375785
[TBL] [Abstract][Full Text] [Related]
28. Voluntary-Opsonization-Enabled Precision Nanomedicines for Inflammation Treatment.
Li S; Li M; Huo S; Wang Q; Chen J; Ding S; Zeng Z; Zhou W; Wang Y; Wang J
Adv Mater; 2021 Jan; 33(3):e2006160. PubMed ID: 33296121
[TBL] [Abstract][Full Text] [Related]
29. The microenvironment and resistance to personalized cancer therapy.
Masuda S; Izpisua Belmonte JC
Nat Rev Clin Oncol; 2013 Feb; 10(2):. PubMed ID: 23247379
[No Abstract] [Full Text] [Related]
30. Real Personalized Medicine.
Armitage JO; Wood WC; Longo DL
J Natl Compr Canc Netw; 2016 Feb; 14(2):233-6. PubMed ID: 26850491
[No Abstract] [Full Text] [Related]
31. Opportunities for glyconanomaterials in personalized medicine.
Reichardt NC; Martín-Lomas M; Penadés S
Chem Commun (Camb); 2016 Nov; 52(92):13430-13439. PubMed ID: 27709147
[TBL] [Abstract][Full Text] [Related]
32. Theranostic barcoded nanoparticles for personalized cancer medicine.
Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
[TBL] [Abstract][Full Text] [Related]
33. Cancer nanomedicine: challenges and opportunities.
Kuncic Z
Med J Aust; 2015 Sep; 203(5):204-5e.1. PubMed ID: 26852043
[No Abstract] [Full Text] [Related]
34. A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.
Sau S; Tatiparti K; Alsaab HO; Kashaw SK; Iyer AK
Drug Discov Today; 2018 Jul; 23(7):1344-1356. PubMed ID: 29551455
[TBL] [Abstract][Full Text] [Related]
35. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
[TBL] [Abstract][Full Text] [Related]
36. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting.
Fu X; Shi Y; Qi T; Qiu S; Huang Y; Zhao X; Sun Q; Lin G
Signal Transduct Target Ther; 2020 Nov; 5(1):262. PubMed ID: 33154350
[TBL] [Abstract][Full Text] [Related]
37. Editorial. Approaches to personalized medicine in oncology--the 9th Annual Meeting of CESAR in Greifswald.
Ritter C; Sehrt D; Jaehde U
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):53-4. PubMed ID: 22192647
[No Abstract] [Full Text] [Related]
38. Gene and drug matrix for personalized cancer therapy.
Harris T
Nat Rev Drug Discov; 2010 Aug; 9(8):660. PubMed ID: 20671766
[No Abstract] [Full Text] [Related]
39. Genomics, personalized medicine, and supportive cancer care.
Sonis ST
Am Soc Clin Oncol Educ Book; 2015; ():9-16. PubMed ID: 25993135
[No Abstract] [Full Text] [Related]
40. Animal models for personalized treatment options.
Fichtner I; Klinghammer K; Behrens D; Flechsig S; Rolff J; Becker M; Wulf-Goldenberg A; Stecklum M; Rivera M; Brzezicha B; Jandrig B; Hoffmann J
Int J Clin Pharmacol Ther; 2017 Aug; 55(8):698-700. PubMed ID: 28696202
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
